VISTAGEN THERAPEUTICS, INC. Operating Lease, Payments
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Operating Lease, Payments of $700.00 thousand for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-15.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-06-15
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for the quarter ending 2023-06-30 was $223.10K, a 8.83% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for the quarter ending 2023-03-31 was $244.80K, a 18.55% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for the quarter ending 2022-12-31 was $228.80K, a 10.48% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for the quarter ending 2022-09-30 was $221.40K, a 8.11% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for fiscal 2026 was $700.00K, a 12.50% decline from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for fiscal 2025 was $800.00K, a 14.29% increase from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $700.00K, a 22.22% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $900.00K, a 6.60% increase from fiscal 2022.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $700.00K 10-K · filed 2026-06-15 | ||||
| 2025-03-31 | $800.00K 10-K · filed 2026-06-15 | ||||
| 2024-03-31 | $700.00K 10-K · filed 2025-06-17 | ||||
| 2023-06-30 | $223.10K 10-Q · filed 2023-08-10 | $467.90K derived: sum of 2 quarters · filed 2024-06-11 | $696.70K derived: sum of 3 quarters · filed 2024-06-11 | $918.10K derived: sum of 4 quarters · filed 2024-06-11 | |
| 2023-03-31 | $244.80K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-11 | $473.60K derived: sum of 2 quarters · filed 2024-06-11 | $695.00K derived: sum of 3 quarters · filed 2024-06-11 | $900.00K 10-K · filed 2024-06-11 | $883.20K 10-K · filed 2023-06-28 |
| 2022-12-31 | $228.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-07 | $450.20K derived: sum of 2 quarters · filed 2023-02-07 | $655.20K 10-Q · filed 2023-02-07 | $861.70K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-09-30 | $221.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-10 | $426.40K 10-Q · filed 2022-11-10 | $632.90K derived: sum of 3 quarters · filed 2023-08-10 | $840.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-06-30 | $205.00K 10-Q · filed 2023-08-10 | $411.50K derived: sum of 2 quarters · filed 2023-08-10 | $618.60K derived: sum of 3 quarters · filed 2023-08-10 | $823.40K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $206.50K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $413.60K derived: sum of 2 quarters · filed 2023-06-28 | $618.40K derived: sum of 3 quarters · filed 2023-06-28 | $844.30K 10-K · filed 2023-06-28 | |
| 2021-12-31 | $207.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-07 | $411.90K derived: sum of 2 quarters · filed 2023-02-07 | $637.80K 10-Q · filed 2023-02-07 | $838.80K derived: sum of 4 quarters · filed 2023-02-07 | |
| 2021-09-30 | $204.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-10 | $430.70K 10-Q · filed 2022-11-10 | $631.70K derived: sum of 3 quarters · filed 2022-11-10 | $829.20K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $225.90K 10-Q · filed 2022-08-11 | $426.90K derived: sum of 2 quarters · filed 2022-08-11 | $624.40K derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $398.50K derived: sum of 2 quarters · filed 2022-06-23 | $791.60K 10-K · filed 2022-06-23 | ||
| 2020-12-31 | $197.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-10 | $590.60K 10-Q · filed 2022-02-10 | |||
| 2020-09-30 | $393.10K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |